This post was originally published on this site
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
Headline
European Committee Takes a Second Look at Alzheimer’s Drug and Now Says It Should Be …
Back To Top